PARIS (Reuters) – France has ordered 50,000 doses of Merck & Co’s experimental COVID-19 antiviral drug for adults, the country’s health minister Olivier Veran told a hearing at the French Senate on Tuesday.
“France positioned itself very early in pre-ordering. France ordered 50,000 doses of the drug,” Veran told lawmakers about molnupiravir, which is Merck & Co’s experimental antiviral pills to treat COVID-19 ailments.
Governments around the world are preparing to ensure they can cope any pick-up in the COVID virus as the winter season approaches in the northern hemisphere.
Merck & Co said on Monday that the European Union’s drug regulator had initiated a real-time review of its experimental COVID antiviral drug for adults.
While vaccines are the main weapons against COVID-19, Merck’s experimental pill molnupiravir could be a game-changer after studies showed it could halve the chances of dying or being hospitalised for those most at risk of contracting severe illness.
(Reporting by Matthieu Protard; Editing by Sudip Kar-Gupta)
